These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 19342857)

  • 1. Long-term low-dose spironolactone therapy is safe in oligoanuric hemodialysis patients.
    Matsumoto Y; Kageyama S; Yakushigawa T; Arihara K; Sugiyama T; Mori Y; Sugiyama H; Ohmura H; Shio N
    Cardiology; 2009; 114(1):32-8. PubMed ID: 19342857
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Spironolactone-induced renal insufficiency and hyperkalemia in patients with heart failure.
    Tamirisa KP; Aaronson KD; Koelling TM
    Am Heart J; 2004 Dec; 148(6):971-8. PubMed ID: 15632880
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum concentration of potassium in chronic heart failure patients administered spironolactone plus furosemide and either enalapril maleate, losartan potassium or candesartan cilexetil.
    Saito M; Takada M; Hirooka K; Isobe F; Yasumura Y
    J Clin Pharm Ther; 2005 Dec; 30(6):603-10. PubMed ID: 16336294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical experience with spironolactone in pediatrics.
    Buck ML
    Ann Pharmacother; 2005 May; 39(5):823-8. PubMed ID: 15811903
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Appropriateness and complications of the use of spironolactone in patients treated in a heart failure clinic.
    Goland S; Naugolny V; Korbut Z; Rozen I; Caspi A; Malnick S
    Eur J Intern Med; 2011 Aug; 22(4):424-7. PubMed ID: 21767763
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Eplerenone: new drug. Recent myocardial infarction with heart failure: a spironolactone me too.
    Prescrire Int; 2006 Apr; 15(82):46-9. PubMed ID: 16604728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized controlled trial of fludrocortisone for the treatment of hyperkalemia in hemodialysis patients.
    Kaisar MO; Wiggins KJ; Sturtevant JM; Hawley CM; Campbell SB; Isbel NM; Mudge DW; Bofinger A; Petrie JJ; Johnson DW
    Am J Kidney Dis; 2006 May; 47(5):809-14. PubMed ID: 16632019
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Abolghasmi R; Taziki O
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure.
    Shah KB; Rao K; Sawyer R; Gottlieb SS
    J Am Coll Cardiol; 2005 Sep; 46(5):845-9. PubMed ID: 16139135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New strategies for treatment of heart failure with aldosterone antagonists and the risk of hyperkalaemia.
    Cruz CS; Cruz LS; Domingues GS; Souza CA
    Expert Opin Drug Saf; 2005 Jul; 4(4):677-88. PubMed ID: 16011447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tolerability of spironolactone in patients with chronic heart failure -- a cautionary message.
    Witham MD; Gillespie ND; Struthers AD
    Br J Clin Pharmacol; 2004 Nov; 58(5):554-7. PubMed ID: 15521905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Appropriateness of spironolactone prescribing in heart failure patients: a population-based study.
    Ko DT; Juurlink DN; Mamdani MM; You JJ; Wang JT; Donovan LR; Tu JV
    J Card Fail; 2006 Apr; 12(3):205-10. PubMed ID: 16624686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequency and predictors of hyperkalemia in patients ≥60 years of age with heart failure undergoing intense medical therapy.
    Muzzarelli S; Maeder MT; Toggweiler S; Rickli H; Nietlispach F; Julius B; Burkard T; Pfisterer ME; Brunner-La Rocca HP;
    Am J Cardiol; 2012 Mar; 109(5):693-8. PubMed ID: 22152974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Laboratory evaluation of potassium and creatinine among ambulatory patients prescribed spironolactone: are we monitoring for hyperkalemia?
    Raebel MA; McClure DL; Chan KA; Simon SR; Feldstein AC; Lafata JE; Andrade SE; Gunter MJ; Nelson WW; Roblin D; Platt R
    Ann Pharmacother; 2007 Feb; 41(2):193-200. PubMed ID: 17284506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors predicting hyperkalemia in patients with cirrhosis receiving spironolactone.
    Abbas Z; Mumtaz K; Salam A; Jafri W
    J Coll Physicians Surg Pak; 2003 Jul; 13(7):382-4. PubMed ID: 12887837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of low-dose spironolactone administration in chronic haemodialysis patients.
    Saudan P; Mach F; Perneger T; Schnetzler B; Stoermann C; Fumeaux Z; Rossier M; Martin PY
    Nephrol Dial Transplant; 2003 Nov; 18(11):2359-63. PubMed ID: 14551366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot randomised double-blind controlled trial of high-dose spironolactone in critically ill patients receiving a frusemide infusion.
    Apte Y; Bellomo R; Warrillow S; Goldsmith D; Gillies M; McGain F
    Crit Care Resusc; 2008 Dec; 10(4):306-11. PubMed ID: 19049481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is spironolactone safe for dialysis patients?
    Hussain S; Dreyfus DE; Marcus RJ; Biederman RW; McGill RL
    Nephrol Dial Transplant; 2003 Nov; 18(11):2364-8. PubMed ID: 14551367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of heart failure with spironolactone--trial and tribulations.
    McMurray JJ; O'Meara E
    N Engl J Med; 2004 Aug; 351(6):526-8. PubMed ID: 15295043
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of spironolactone on K(+) homeostasis and ENaC expression in lymphocytes from chronic hemodialysis patients.
    Michea L; Vukusich A; González M; Zehnder C; Marusic ET
    Kidney Int; 2004 Oct; 66(4):1647-53. PubMed ID: 15458462
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.